scholarly journals Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart

2019 ◽  
Vol 21 (9) ◽  
pp. 2068-2075 ◽  
Author(s):  
Thomas R. Pieber ◽  
Eva Svehlikova ◽  
Martina Brunner ◽  
Inge B. Halberg ◽  
Karen Margrete Due Thomsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Initial Exposure ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Acting Insulin ◽  
Glucose Lowering Effect ◽  
Fast Acting

scholarly journals Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences

2020 ◽  
Vol 23 (2) ◽  
pp. 140-160
Author(s):  
Hanne Haahr ◽  
Tim Heise
Keyword(s):  
Clinical Pharmacology ◽  
Insulin Aspart ◽  
Postprandial Glucose ◽  
Phase Iii ◽  
Initial Exposure ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Acting Insulin ◽  
Glucose Lowering Effect ◽  
Fast Acting

Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinetic/pharmacodynamic properties of faster aspart have been characterised in clinical pharmacology trials with comparable overall methodology. In subjects with type 1 (T1D) or type 2 (T2D) diabetes, the serum IAsp concentration-time and glucose-lowering effect profiles are left-shifted for faster aspart compared with IAsp. In addition, faster aspart provides earlier onset, doubling of initial exposure, and an up to 2.5-fold increase in initial glucose-lowering effect within 30 min of subcutaneous injection, as well as earlier offset of exposure and effect. Similar results have been shown using continuous subcutaneous insulin infusion (CSII). The improved pharmacological properties of faster aspart versus IAsp are consistent across populations, i.e. in the elderly, children, adolescents and the Japanese. Thus, the faster aspart pharmacological characteristics more closely resemble the mealtime insulin secretion in healthy individuals, giving faster aspart the potential to further improve postprandial glucose control in subjects with diabetes. Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.

Prior meal enhances the plasma glucose lowering effect of exercise in type 2 diabetes

2001 ◽  
Vol 33 (8) ◽  
pp. 1259-1264 ◽  
Author(s):  
PAUL POIRIER ◽  
SAMANTHA MAWHINNEY ◽  
LUC GRONDIN ◽  
ANGELO TREMBLAY ◽  
TOM BRODERICK ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect
Sign in / Sign up

Export Citation Format

Share Document